

20:33 20 Aug 2020

Imugene receives third ethics approval to start phase-1 clinical trial of PD1-Vaxx cancer immunotherapy

Imugene Ltd (ASX:IMU) (OTCMKTS:IUGNF) has received a third Human Research Ethics Committee (HREC) approval to begin a phase-1 human trial of anti-cancer immunotherapy candidate PD1-Vaxx in Australia.

Ethics approval is confirmation that Imugene has completed all the necessary pre-clinical safety and efficacy testing of PD1-Vaxx required to start human clinical trials.

The third hospital to receive ethics approval is the Cabrini hospital in Melbourne, Australia.

Additional sites are being profiled in Australia and the US following a Food and Drug Administration (FDA) investigational new drug (IND) submission.

"Significant milestone"

Managing director and CEO Leslie Chong said: "The start of our Australian study is a significant milestone for Imugene and clinicians treating Australians faced with the challenge of lung cancer."

Shares have been as much as 11% higher this morning to A\$0.062.

In further progress towards commencing clinical dosing, patient screening has started at Macquarie University Hospital, which has already received its ethics approval.

The first-in-human, Phase 1, multi-centre, dose-escalation study of PD1-Vaxx will involve patients with non-small cell lung cancer.

Medical investigators will test different doses of PD1-Vaxx as a monotherapy and in combination with immune checkpoint inhibitor drugs.

Chong added: "Receiving a third ethics approval and finalising Macquarie University Hospital site activation process to begin patient screening is exciting."

B-cell cancer immunotherapy


The Australian Lung Foundation estimates 12,800 Australians are diagnosed with lung cancer each year.

Imugene's PD1-Vaxx is B-cell cancer immunotherapy designed to treat tumours such as lung cancer by interfering with PD-1/PD-L1 binding and interaction, and produce an anti-cancer effect similar to Keytruda®, Opdivo® and other immune checkpoint inhibitor monoclonal antibodies that are transforming treatment of a range of cancers.

Price: 0.105

Market Cap: \$497.8 m

1 Year Share Price Graph



Share Information

Code: IMU

Listing: ASX

52 week High Low
0.14 0.016

Sector: Pharma & Biotech

Website: www.imugene.com

Company Synopsis:

Imugene Ltd (ASX:IMU) is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).